Abstract
Summary
The global market for Glanzmann Thrombasthenia Therapeutic Drug was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glanzmann Thrombasthenia Therapeutic Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glanzmann Thrombasthenia Therapeutic Drug by region & country, by Type, and by Application.
The Glanzmann Thrombasthenia Therapeutic Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glanzmann Thrombasthenia Therapeutic Drug.
Market Segmentation
By Company
Novo Nordisk
Alnylam Pharmaceuticals
Shire (Takeda)
Biogen
Bioverativ (Sanofi)
Bayer
CSL Behring
Grifols
Bristol-Myers Squibb
Pfizer
Segment by Type:
Platelet Transfusion
Recombinant Activated Factor VII
Antifibrinolytics
Fibrin Sealants
Thrombin
Desmopressin
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glanzmann Thrombasthenia Therapeutic Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Glanzmann Thrombasthenia Therapeutic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Glanzmann Thrombasthenia Therapeutic Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glanzmann Thrombasthenia Therapeutic Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glanzmann Thrombasthenia Therapeutic Drug by region & country, by Type, and by Application.
The Glanzmann Thrombasthenia Therapeutic Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glanzmann Thrombasthenia Therapeutic Drug.
Market Segmentation
By Company
Novo Nordisk
Alnylam Pharmaceuticals
Shire (Takeda)
Biogen
Bioverativ (Sanofi)
Bayer
CSL Behring
Grifols
Bristol-Myers Squibb
Pfizer
Segment by Type:
Platelet Transfusion
Recombinant Activated Factor VII
Antifibrinolytics
Fibrin Sealants
Thrombin
Desmopressin
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glanzmann Thrombasthenia Therapeutic Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Glanzmann Thrombasthenia Therapeutic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Glanzmann Thrombasthenia Therapeutic Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Glanzmann Thrombasthenia Therapeutic Drug Product Introduction
1.2 Global Glanzmann Thrombasthenia Therapeutic Drug Market Size Forecast
1.3 Glanzmann Thrombasthenia Therapeutic Drug Market Trends & Drivers
1.3.1 Glanzmann Thrombasthenia Therapeutic Drug Industry Trends
1.3.2 Glanzmann Thrombasthenia Therapeutic Drug Market Drivers & Opportunity
1.3.3 Glanzmann Thrombasthenia Therapeutic Drug Market Challenges
1.3.4 Glanzmann Thrombasthenia Therapeutic Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Glanzmann Thrombasthenia Therapeutic Drug Players Revenue Ranking (2023)
2.2 Global Glanzmann Thrombasthenia Therapeutic Drug Revenue by Company (2019-2024)
2.3 Key Companies Glanzmann Thrombasthenia Therapeutic Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Glanzmann Thrombasthenia Therapeutic Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Glanzmann Thrombasthenia Therapeutic Drug
2.6 Glanzmann Thrombasthenia Therapeutic Drug Market Competitive Analysis
2.6.1 Glanzmann Thrombasthenia Therapeutic Drug Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Glanzmann Thrombasthenia Therapeutic Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glanzmann Thrombasthenia Therapeutic Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Platelet Transfusion
3.1.2 Recombinant Activated Factor VII
3.1.3 Antifibrinolytics
3.1.4 Fibrin Sealants
3.1.5 Thrombin
3.1.6 Desmopressin
3.2 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type
3.2.1 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value, by Type (2019-2030)
3.2.3 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application
4.2.1 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value, by Application (2019-2030)
4.2.3 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Region
5.1.1 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Region (2019-2024)
5.1.3 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Region (2025-2030)
5.1.4 Global Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
5.2.2 North America Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
5.3.2 Europe Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
5.5.2 South America Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Glanzmann Thrombasthenia Therapeutic Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Glanzmann Thrombasthenia Therapeutic Drug Sales Value
6.3 United States
6.3.1 United States Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.3.2 United States Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.4.2 Europe Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.5.2 China Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.6.2 Japan Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.7.2 South Korea Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Glanzmann Thrombasthenia Therapeutic Drug Sales Value, 2019-2030
6.9.2 India Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Glanzmann Thrombasthenia Therapeutic Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Profile
7.1.2 Novo Nordisk Main Business
7.1.3 Novo Nordisk Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.1.4 Novo Nordisk Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.1.5 Novo Nordisk Recent Developments
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Profile
7.2.2 Alnylam Pharmaceuticals Main Business
7.2.3 Alnylam Pharmaceuticals Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.2.4 Alnylam Pharmaceuticals Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.2.5 Alnylam Pharmaceuticals Recent Developments
7.3 Shire (Takeda)
7.3.1 Shire (Takeda) Profile
7.3.2 Shire (Takeda) Main Business
7.3.3 Shire (Takeda) Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.3.4 Shire (Takeda) Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Biogen Recent Developments
7.4 Biogen
7.4.1 Biogen Profile
7.4.2 Biogen Main Business
7.4.3 Biogen Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.4.4 Biogen Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Biogen Recent Developments
7.5 Bioverativ (Sanofi)
7.5.1 Bioverativ (Sanofi) Profile
7.5.2 Bioverativ (Sanofi) Main Business
7.5.3 Bioverativ (Sanofi) Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.5.4 Bioverativ (Sanofi) Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Bioverativ (Sanofi) Recent Developments
7.6 Bayer
7.6.1 Bayer Profile
7.6.2 Bayer Main Business
7.6.3 Bayer Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.6.4 Bayer Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Bayer Recent Developments
7.7 CSL Behring
7.7.1 CSL Behring Profile
7.7.2 CSL Behring Main Business
7.7.3 CSL Behring Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.7.4 CSL Behring Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.7.5 CSL Behring Recent Developments
7.8 Grifols
7.8.1 Grifols Profile
7.8.2 Grifols Main Business
7.8.3 Grifols Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.8.4 Grifols Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Grifols Recent Developments
7.9 Bristol-Myers Squibb
7.9.1 Bristol-Myers Squibb Profile
7.9.2 Bristol-Myers Squibb Main Business
7.9.3 Bristol-Myers Squibb Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.9.4 Bristol-Myers Squibb Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.9.5 Bristol-Myers Squibb Recent Developments
7.10 Pfizer
7.10.1 Pfizer Profile
7.10.2 Pfizer Main Business
7.10.3 Pfizer Glanzmann Thrombasthenia Therapeutic Drug Products, Services and Solutions
7.10.4 Pfizer Glanzmann Thrombasthenia Therapeutic Drug Revenue (US$ Million) & (2019-2024)
7.10.5 Pfizer Recent Developments
8 Industry Chain Analysis
8.1 Glanzmann Thrombasthenia Therapeutic Drug Industrial Chain
8.2 Glanzmann Thrombasthenia Therapeutic Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Glanzmann Thrombasthenia Therapeutic Drug Sales Model
8.5.2 Sales Channel
8.5.3 Glanzmann Thrombasthenia Therapeutic Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer